ZD6474 – clinical experience to date

Por Heymach, J V
Publicado em 2005

Two conserved domains in the NGF propeptide are necessary and sufficient for the biosynthesis of correctly processed and biologically active NGF.

Por Suter, U, Heymach, J V, Shooter, E M
Publicado em 1991

EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung...

Por Heymach, J. V., Lockwood, S. J., Herbst, R. S., Johnson, B. E., Ryan, A. J.
Publicado em 2014

Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemo-naïve patients with unresectable malignant pleural mesothelioma

Por Tsao, AS, Harun, N, Lee, J.J, Heymach, J, Pisters, K, Hong, WK, Fujimoto, J, Wistuba, I
Publicado no Clin Lung Cancer (2013)

MicroRNA-related genetic variants in iron regulatory genes, dietary iron intake, microRNAs and lung cancer risk

Por Zhang, L., Ye, Y., Tu, H., Hildebrandt, M. A., Zhao, L., Heymach, J. V., Roth, J. A., Wu, X.
Publicado no Ann Oncol (2017)

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors

Por Morgillo, F, Cascone, T, D'Aiuto, E, Martinelli, E, Troiani, T, Saintigny, P, De Palma, R, Heymach, J V, Berrino, L, Tuccillo, C, Ciardiello, F
Publicado em 2011

A phase II pilot trial of low dose, continuous infusion, or “metronomic”, paclitaxel and oral celecoxib in patients with metastatic melanoma

Por Bhatt, R.S., Merchan, J., Parker, R., Wu, H., Zhang, L., Seery, V., Heymach, J.V, Atkins, M.B., McDermott, D., Sukhatme, V.P.
Publicado em 2010

Endothelial progenitor cell mobilization by preoperative exercise: a bone marrow response associated with postoperative outcome

Por Schier, R., El-Zein, R., Cortes, A., Liu, M., Collins, M., Rafat, N., Teschendorf, P., Wu, Hua-Kang, Heymach, J., Mehran, R., Riedel, B.
Publicado no Br J Anaesth (2014)

Membrane carbonic anhydrase IX (CAIX) expression and relapse risk in resected stage I-II non-small cell lung cancer

Por Stewart, D.J., Nunez, M.I., Behrens, C., Liu, D., Lin, Y. H., Lee, J.J., Roth, J., Heymach, J., Swisher, S., Hong, W.K., Wistuba, I.I.
Publicado em 2014

Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma

Por Zurita, A J, Gagnon, R C, Liu, Y, Tran, H T, Figlin, R A, Hutson, T E, D'Amelio Jr, A M, Sternberg, C N, Pandite, L N, Heymach, J V
Publicado no Br J Cancer (2017)

Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma

Por Bhatt, R S, Zurita, A J, O'Neill, A, Norden-Zfoni, A, Zhang, L, Wu, H K, Wen, P Y, George, D, Sukhatme, V P, Atkins, M B, Heymach, J V
Publicado em 2011

Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma

Por Massarelli, E., Lin, H., Ginsberg, L. E., Tran, H. T., Lee, J. J., Canales, J. R., Williams, M. D., Blumenschein, G. R., Lu, C., Heymach, J. V., Kies, M. S., Papadimitrakopoulou, V.
Publicado no Ann Oncol (2015)

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

Por Zurita, A. J., Jonasch, E., Wang, X., Khajavi, M., Yan, S., Du, D. Z., Xu, L., Herynk, M. H., McKee, K. S., Tran, H. T., Logothetis, C. J., Tannir, N. M., Heymach, J. V.
Publicado em 2012

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours

Por Zurita, A J, Khajavi, M, Wu, H-K, Tye, L, Huang, X, Kulke, M H, Lenz, H-J, Meropol, N J, Carley, W, DePrimo, S E, Lin, E, Wang, X, Harmon, C S, Heymach, J V
Publicado no Br J Cancer (2015)

Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer

Por Chen, Z-Y, Raghav, K, Lieu, C H, Jiang, Z-Q, Eng, C, Vauthey, J-N, Chang, G J, Qiao, W, Morris, J, Hong, D, Hoff, P, Tran, H, Menter, D G, Heymach, J, Overman, M, Kopetz, S
Publicado no Br J Cancer (2015)

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up

Por Kadara, H, Choi, M, Zhang, J, Parra, E R, Rodriguez-Canales, J, Gaffney, S G, Zhao, Z, Behrens, C, Fujimoto, J, Chow, C, Yoo, Y, Kalhor, N, Moran, C, Rimm, D, Swisher, S, Gibbons, D L, Heymach, J, Kaftan, E, Townsend, J P, Lynch, T J, Schlessinger, J, Lee, J, Lifton, R P, Wistuba, I I, Herbst, R S
Publicado no Ann Oncol (2017)

Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function

Por Choi, M., Kadara, H., Zhang, J., Parra, E.R., Rodriguez-Canales, J., Gaffney, S.G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., Kim, K., Kalhor, N., Moran, C., Rimm, D., Swisher, S., Gibbons, D.L., Heymach, J., Kaftan, E., Townsend, J.P., Lynch, T.J., Schlessinger, J., Lee, J., Lifton, R.P., Herbst, R.S., Wistuba, I.I.
Publicado no Ann Oncol (2017)